CN108853514A - 具有两种不同药物的抗体药物偶联物 - Google Patents
具有两种不同药物的抗体药物偶联物 Download PDFInfo
- Publication number
- CN108853514A CN108853514A CN201810943787.3A CN201810943787A CN108853514A CN 108853514 A CN108853514 A CN 108853514A CN 201810943787 A CN201810943787 A CN 201810943787A CN 108853514 A CN108853514 A CN 108853514A
- Authority
- CN
- China
- Prior art keywords
- antibody
- drug conjugates
- different pharmaceutical
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*C(C)CC1CC(CC=C2CCCC2)C1 Chemical compound C*C(C)CC1CC(CC=C2CCCC2)C1 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
ADC编号 | 非定点偶联平均DAR1 | 定点偶联平均DAR2 |
Cet-4S-2M | 3.81(S) | 1.78(M) |
Cet-8S-4M | 6.35(S) | 2.97(M) |
Cet-8E-2M | 7.54(E) | 1.78(M) |
Cet-4M | -- | 3.67(M) |
Cet-8S | 7.56(S) | -- |
Cet-8E | 7.92(E) | -- |
目标偶联物 | 单体率 |
Cet-4S-2M | 84.60% |
Cet-8S-4M | 83.87% |
Cet-8E-2M | 92.91% |
Cet-4M | 99.82% |
ADC编号 | IC50(Fadu)(nm) | IC50(A431)(nm) |
Cet-8S-2M | 1.85 | 4.23 |
Cet-8S-4M | 1.18 | 0.15 |
Cet-8E-2M | 200~1000 | 0.08 |
Cet-4M | 200~1000 | 0.06 |
Cet-8S | 1.02 | 8.49 |
Cet-8E | ~200 | >1000 |
Claims (17)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017107103375 | 2017-08-18 | ||
CN201710710337 | 2017-08-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108853514A true CN108853514A (zh) | 2018-11-23 |
CN108853514B CN108853514B (zh) | 2022-07-22 |
Family
ID=64318201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810943787.3A Active CN108853514B (zh) | 2017-08-18 | 2018-08-18 | 具有两种不同药物的抗体药物偶联物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN108853514B (zh) |
WO (1) | WO2019034177A1 (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
CN110974975A (zh) * | 2019-12-12 | 2020-04-10 | 四川百利药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
CN111362926A (zh) * | 2018-12-26 | 2020-07-03 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物的中间体cla-sn38的合成方法及其中间体 |
CN111363005A (zh) * | 2018-12-26 | 2020-07-03 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物中间体clb-sn38的合成方法 |
CN111378006A (zh) * | 2018-12-28 | 2020-07-07 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物的新型双臂中间体lnd1026-035及其合成方法 |
WO2020146541A3 (en) * | 2019-01-08 | 2020-08-13 | Regeneron Pharmaceuticals, Inc. | Traceless linkers and protein-conjugates thereof |
CN111643676A (zh) * | 2020-07-10 | 2020-09-11 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性二聚体、双特异性二聚体-药物偶联物及其应用 |
CN111686259A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
WO2020259258A1 (zh) * | 2019-06-28 | 2020-12-30 | 上海复旦张江生物医药股份有限公司 | 一种抗体偶联药物、其中间体、制备方法及应用 |
WO2021022678A1 (zh) * | 2019-08-07 | 2021-02-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
WO2021190602A1 (zh) | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
WO2021190581A1 (zh) | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
WO2022048521A1 (zh) | 2020-09-01 | 2022-03-10 | 荣昌生物制药(烟台)股份有限公司 | 抗c-Met抗体药物偶联物及其应用 |
US11377502B2 (en) | 2018-05-09 | 2022-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
WO2022194257A1 (zh) * | 2021-03-17 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
WO2022237666A1 (zh) | 2021-05-08 | 2022-11-17 | 荣昌生物制药(烟台)股份有限公司 | 一种抗Claudin18.2抗体及其抗体药物偶联物 |
US11760775B2 (en) | 2016-11-08 | 2023-09-19 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3946464T3 (pl) | 2019-03-29 | 2022-12-19 | Medimmune Limited | Związki i ich koniugaty |
WO2020233174A1 (zh) | 2019-05-20 | 2020-11-26 | 烟台迈百瑞国际生物医药有限公司 | 一种抗体药物偶联物中间体的一锅法制备工艺 |
CN113941007A (zh) * | 2020-07-16 | 2022-01-18 | 成都科岭源医药技术有限公司 | 一种串联的双药物链接组装单元及其应用 |
EP4313164A1 (en) * | 2021-03-31 | 2024-02-07 | RemeGen Co., Ltd. | Preparation and purification method for antibody drug conjugate intermediate |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106132431A (zh) * | 2013-10-15 | 2016-11-16 | 索伦托治疗有限公司 | 具有靶向分子和两种不同药物的药物偶联物 |
EP3107557B1 (en) * | 2014-02-17 | 2021-06-09 | Seagen Inc. | Hydrophilic antibody-drug conjugates |
CN106467575B (zh) * | 2015-08-18 | 2020-07-31 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物 |
CN106866822A (zh) * | 2016-12-25 | 2017-06-20 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体‑毒素偶联物 |
-
2018
- 2018-08-18 CN CN201810943787.3A patent/CN108853514B/zh active Active
- 2018-08-18 WO PCT/CN2018/101215 patent/WO2019034177A1/zh active Application Filing
Non-Patent Citations (3)
Title |
---|
姚文兵 等: "《生物技术制药概论》", 30 August 2015, 中国医药科技出版社 * |
杨铁军: "《产业专利分析报告 第36册》", 30 June 2015, 知识产权出版社 * |
王晓良: "《应用分子药理学》", 30 September 2015, 中国协和医科大学出版社 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11760775B2 (en) | 2016-11-08 | 2023-09-19 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
US11377502B2 (en) | 2018-05-09 | 2022-07-05 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
CN111362926A (zh) * | 2018-12-26 | 2020-07-03 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物的中间体cla-sn38的合成方法及其中间体 |
CN111363005A (zh) * | 2018-12-26 | 2020-07-03 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物中间体clb-sn38的合成方法 |
CN111362926B (zh) * | 2018-12-26 | 2021-04-30 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物的中间体cla-sn38的合成方法及其中间体 |
CN111363005B (zh) * | 2018-12-26 | 2021-08-17 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物中间体clb-sn38的合成方法 |
CN111378006A (zh) * | 2018-12-28 | 2020-07-07 | 联宁(苏州)生物制药有限公司 | 一种用于抗体偶联药物的新型双臂中间体lnd1026-035及其合成方法 |
WO2020146541A3 (en) * | 2019-01-08 | 2020-08-13 | Regeneron Pharmaceuticals, Inc. | Traceless linkers and protein-conjugates thereof |
CN111686259B (zh) * | 2019-05-26 | 2023-08-08 | 成都百利多特生物药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
CN111686259A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
WO2020259258A1 (zh) * | 2019-06-28 | 2020-12-30 | 上海复旦张江生物医药股份有限公司 | 一种抗体偶联药物、其中间体、制备方法及应用 |
WO2021022678A1 (zh) * | 2019-08-07 | 2021-02-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
US11596693B2 (en) | 2019-08-07 | 2023-03-07 | Mabplex International Co., Ltd | Antibody-drug conjugates and uses thereof |
CN110974975B (zh) * | 2019-12-12 | 2023-10-20 | 成都百利多特生物药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
CN110974975A (zh) * | 2019-12-12 | 2020-04-10 | 四川百利药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
WO2021190581A1 (zh) | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
WO2021190602A1 (zh) | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
CN111643676A (zh) * | 2020-07-10 | 2020-09-11 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性二聚体、双特异性二聚体-药物偶联物及其应用 |
CN111643676B (zh) * | 2020-07-10 | 2023-06-30 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性二聚体、双特异性二聚体-药物偶联物及其应用 |
TWI817190B (zh) * | 2020-09-01 | 2023-10-01 | 大陸商榮昌生物製藥(煙臺)股份有限公司 | 抗c-Met抗體藥物偶聯物及其應用 |
WO2022048521A1 (zh) | 2020-09-01 | 2022-03-10 | 荣昌生物制药(烟台)股份有限公司 | 抗c-Met抗体药物偶联物及其应用 |
WO2022194257A1 (zh) * | 2021-03-17 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
WO2022237666A1 (zh) | 2021-05-08 | 2022-11-17 | 荣昌生物制药(烟台)股份有限公司 | 一种抗Claudin18.2抗体及其抗体药物偶联物 |
Also Published As
Publication number | Publication date |
---|---|
CN108853514B (zh) | 2022-07-22 |
WO2019034177A1 (zh) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108853514A (zh) | 具有两种不同药物的抗体药物偶联物 | |
CN106459055B (zh) | 双功能细胞毒类药剂 | |
CN108452321B (zh) | 一种带酸性自稳定接头的抗体-药物偶联物 | |
CN104784699B (zh) | 叶酸受体结合配体-药物偶联物 | |
KR102647074B1 (ko) | 친수성 항체-약물 컨쥬게이트 | |
JP2024038168A (ja) | 生物活性分子コンジュゲート、その調製法及び使用 | |
CN114456186B (zh) | 一种喜树碱类衍生物及其配体-药物偶联物 | |
CN109106951A (zh) | 一种喜树碱-抗体偶联物 | |
CN106604927B (zh) | 细胞毒性苯并二氮杂䓬衍生物 | |
KR101413955B1 (ko) | 아지리디닐-에포틸론 화합물 | |
CN105813653A (zh) | 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物 | |
CN106749665A (zh) | Cc‑1065类似物和双功能接头的新型缀合物 | |
JP2023529415A (ja) | 高安定性の親水性結合ユニットを有するカンプトテシン類薬物及びその複合体 | |
CN104244718A (zh) | 抗体-药物缀合物以及相关化合物、组合物和方法 | |
CN111001012A (zh) | 一种亲水碳酸酯型抗体偶联药物 | |
TWI712605B (zh) | 含有cti藥效基團之雙功能性細胞毒性劑 | |
CN111686259A (zh) | 一种含sn38的抗体药物偶联物 | |
CN110974975A (zh) | 一种快速释放的抗体药物偶联物 | |
AU2017340314B2 (en) | Cysteine modified antibody-drug conjugate and preparation method thereof | |
US11319341B2 (en) | Immune-stimulating soluble doxorubicin-conjugated complex | |
TW201818974A (zh) | 抗體藥物複合體 | |
CN116036303A (zh) | 一种抗体-药物偶联物及其制备方法和应用 | |
RU2793125C2 (ru) | Конъюгат антитело-лекарственное средство, имеющий кислотный самостабилизирующийся участок соединения | |
WO2023208168A1 (zh) | 一种包含亲水性糖结构的配体-药物偶联物 | |
CN107660208A (zh) | 包含cti药效团的双功能细胞毒性剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210705 Address after: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant after: Sichuan Baili Pharm Co.,Ltd. Applicant after: Chengdu duote antibody medicine Co.,Ltd. Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant before: Sichuan Baili Pharm Co.,Ltd. |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant after: SICHUAN BAILI PHARM Co.,Ltd. Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant before: SICHUAN BAILI PHARM Co.,Ltd. Applicant before: Chengdu duote antibody medicine Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221114 Address after: 610000 Building 1, No. 161 Baili Road, Chengdu cross strait science and Technology Industrial Development Park, Wenjiang District, Chengdu, Sichuan Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. Address before: 611130 Chengdu cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Patentee before: SICHUAN BAILI PHARM Co.,Ltd. Patentee before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. |